MedTrace Logo

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

NCT02520518 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-01-03

Study results available
· View outcomes & findings →

Summary

Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2) inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight (fat) loss, in addition to other health benefits, including decreased blood pressure, decreased inflammation, and decreased oxidative stress. It is unclear as to whether these health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.

Conditions

Interventions

DRUG

Dapagliflozin

DRUG

Placebo

BEHAVIORAL

Weight maintenance

BEHAVIORAL

Ad libitum dietary intake

BEHAVIORAL

Dietary restriction

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Christopher Bell

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520518 on ClinicalTrials.gov